Defense World
21 Feb 2026, 09:10 UTC · 28w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
Search tags
What the story claims
2 claims · each scored for market impact
Five out of seven research firms covering Pyxis Oncology have assigned a 'buy' rating to the stock. — Strong analyst consensus generally supports upward price pressure and positive investor sentiment.
+0.40Pyxis Oncology has an average analyst recommendation of 'Moderate Buy'. — A moderate buy rating suggests a generally positive but not aggressively bullish outlook from the analyst community.
+0.20Which stocks this story touches
The company has a 'Moderate Buy' average recommendation with a majority of analysts assigning buy ratings.
Continue reading
5 related stories
Read next
Seeking Alpha · 1d ago
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Benzinga
1h ago
